The bill, H.B. No. 3057, aims to establish network standards for Chimeric Antigen Receptor T-Cell (CAR T) therapy within the Texas Insurance Code by creating Chapter 1381. The purpose of this chapter is to expand access to CAR T therapy by ensuring that if the treatment is covered by a health benefit plan, it can be administered at any certified healthcare facility that meets the safety and training standards set by the Food and Drug Administration (FDA). The chapter applies to various health benefit plans, including individual and group insurance policies, and mandates that these plans cannot refuse to contract with or deny coverage for certified providers of CAR T therapy.

Additionally, the bill stipulates that health benefit plans must comply with these network standards starting January 1, 2026, and empowers the commissioner to adopt necessary rules for the administration of the chapter. The act is set to take effect on September 1, 2025. Overall, the legislation seeks to enhance patient access to innovative cancer treatments by ensuring that coverage is not limited by provider networks.

Statutes affected:
Introduced: ()